


ORIGINAL RESEARCH

Regulation of the Pancreatic Exocrine Differentiation Program and Morphogenesis by Onecut 1/Hnf6

Peter A. Kropp,¹ Xiaodong Zhu,^{2,3} and Maureen Gannon^{1,2,3,4}

¹Department of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, Tennessee; ²Department of Veterans Affairs, Tennessee Valley Health Authority, Nashville, Tennessee; ³Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; ⁴Department of Cell & Developmental Biology, Vanderbilt University, Nashville, Tennessee



SUMMARY

Using RNA-Seq we analyzed gene expression changes associated with *Oc1/Hnf6* loss in mouse pancreas. We performed chromatin immunoprecipitation sequencing to identify direct transcriptional targets of *Oc1/Hnf6* in pancreatic exocrine tissue. Our results solidify a role for *Oc1/Hnf6* in establishing pancreas identity and suggest that duct/acinar identity is dependent on differential levels of *Oc1/Hnf6* expression.

BACKGROUND & AIMS: The Onecut 1 transcription factor (*Oc1*, a.k.a. HNF6) promotes differentiation of endocrine and duct cells of the pancreas; however, it has no known role in acinar cell differentiation. We sought to better understand the role of *Oc1* in exocrine pancreas development and to identify its direct transcriptional targets.

METHODS: Pancreata from *Oc1*^{Δpanc} (*Oc1*^{f/f}; *Pdx1-Cre*) mouse embryos and neonates were analyzed morphologically. High-throughput RNA-sequencing was performed on control and *Oc1*-deficient pancreas; chromatin immunoprecipitation sequencing was performed on wild-type embryonic mouse pancreata to identify direct *Oc1* transcriptional targets. Immunofluorescence labeling was used to confirm the RNA-sequencing /chromatin immunoprecipitation sequencing results and to further investigate the effects of *Oc1* loss on acinar cells.

RESULTS: Loss of *Oc1* from the developing pancreatic epithelium resulted in disrupted duct and acinar cell development. RNA-sequencing revealed decreased expression of acinar cell regulatory factors (*Nr5a2*, *Ptf1a*, *Gata4*, *Mist1*) and functional genes (*Amylase*, *Cpa1*, *Prss1*, *Spink1*) at embryonic day (e) 18.5 in *Oc1*^{Δpanc} samples. Approximately 1000 of the altered genes were also identified as direct *Oc1* targets by chromatin immunoprecipitation sequencing, including most of the previously noted genes. By immunolabeling, we confirmed that *Amylase*, *Mist1*, and *GATA4* protein levels are significantly decreased by P2, and *Spink1* protein levels were significantly reduced and mislocalized. The pancreatic duct regulatory factors *Hnf1β* and *FoxA2* were also identified as direct *Oc1* targets.

CONCLUSIONS: These findings confirm that *Oc1* is an important regulator of both duct and acinar cell development in the embryonic pancreas. Novel transcriptional targets of *Oc1* have now been identified and provide clarity into the mechanisms of *Oc1* transcriptional regulation in the developing exocrine pancreas. *Oc1* can now be included in the gene-regulatory network of acinar cell regulatory genes. *Oc1* regulates other acinar cell regulatory factors and acinar cell functional genes directly, and it can also regulate some acinar cell regulatory factors (eg, *Mist1*) indirectly. *Oc1* therefore plays an important role in acinar cell development. (*Cell Mol Gastroenterol Hepatol* 2019;7:841–856; <https://doi.org/10.1016/j.jcmgh.2019.02.004>)

Keywords: Pancreas Development; Exocrine; Transcriptome.

Background and Aims

The exocrine pancreas serves a vital function in digestion through production and transport of digestive enzymes. The pancreatic acinar cells produce and secrete digestive enzymes into the lumen of the pancreatic ducts, which in turn transport them to the rostral duodenum. The exocrine pancreas is also the source of serious diseases, such as pancreatitis, intrapapillary mucinous neoplasia, and pancreatic ductal adenocarcinoma (PDAC). The most serious of these, PDAC, afflicts more than 50,000 individuals in the United States every year with only approximately 8% of diagnosed individuals surviving past 5 years.¹ In spite of its name and histologic appearance, PDAC is believed to originate from the pancreatic acinar cells.² PDAC development and progression are marked by re-activation of pathways associated with exocrine pancreas development including Wnt, Notch, and Hedgehog (HH) signaling as well as decreased expression of transcription factors that regulate acinar cell identity.³ For that reason, a more complete understanding of exocrine pancreas development and maintenance of acinar differentiation will provide better avenues to therapeutic approaches.


All cells of the pancreas originate from a pool of multipotent pancreatic progenitor cells (MPCs).⁴ Specification and differentiation of pancreatic cell types is orchestrated by a cascade of transcription factors. Two of the most upstream of these are the forkhead box family members *Foxa1* and *Foxa2*. Together they redundantly regulate expression of the essential pancreatic transcription factor, *Pdx1* (pancreatic and duodenal homeobox 1). In the absence of *Foxa1* and *Foxa2*, *Pdx1* expression is lost and severe pancreatic hypoplasia results.⁵ Many pancreas transcription factors are initially broadly expressed and then become increasingly restricted to particular cell fates, whereas others are activated specifically in lineage-restricted cells. For example, *Pdx1* is initially expressed in all MPCs but as development progresses, it becomes highly upregulated in the β -cell lineage. It is still present at low levels in mature acinar cells and becomes downregulated in ducts.⁶ The transcription factors *Ptf1a* (*Pancreas transcription factor, 1a*) and *Nr5a2* (*Nuclear receptor subfamily 5, group A, member 2*) are expressed in MPCs but become restricted to mature acinar cells,⁷⁻¹⁴ whereas *Mist1* (*muscle, intestine, stomach transcription factor 1*) is only expressed once cells have become committed to an acinar cell fate.¹⁵⁻¹⁷ Similar to *Ptf1a* and *Nr5a2*, *Hnf1 β* (*Hepatocyte nuclear factor 1 β*) and *Sox9* (*SRY-related HMG-box 9*) are transcription factors expressed in MPCs; however, they become restricted to mature duct cells.¹⁸⁻²⁵ These factors all have key roles in regulating the development, function, and identity of the cell type in which they are expressed. *Ptf1a* inactivation in development results in near complete pancreatic agenesis, and inactivation in adults results in loss of acinar cell identity.⁷⁻¹⁰ *Nr5a2* inactivation in development results in a severely hypoplastic pancreas with a disproportionate loss of acinar cells. Loss of *Sox9* during pancreas development results in pancreas hypoplasia, whereas inactivation in adults sensitizes duct cells to dysplasia.^{2,20,23,24} *Hnf1 β* -null mice similarly develop a

severely hypoplastic pancreatic bud, and inactivation later in development results in duct dysmorphogenesis and loss of ductal primary cilia.^{18,19,21,22} These studies all demonstrate the importance of lineage-restricted transcription factors in regulation of exocrine pancreas development.

The *Onecut1* (*Oc1*, formally known as *Hepatocyte nuclear factor 6* [*Hnf6*]) transcription factor is also expressed in MPCs but, unlike the previously mentioned factors, in adults it is expressed in both acinar and duct cells where it is expressed at a low and high level, respectively.^{26,27} *Oc1* plays important roles in activating the endocrine specification program during pancreas development^{27,28} and during differentiation of the pancreatic ducts.²⁶ *Oc1* inactivation throughout the pancreatic epithelium in early pancreas development results in a hypoplastic pancreas, ductal cysts, duct hyperplasia, a multilayered duct epithelium, and loss of primary cilia.^{26,27,29} Additionally, *Oc1* inactivation during development results in postnatal acinar cell defects resembling pancreatitis including fibrosis, acinar-to-ductal metaplasia (ADM), and inflammation,^{27,29} suggesting a role for *Oc1* in regulation of both duct and acinar cell development. These findings are further supported by human PDAC studies that correlate progression of precancerous lesions (pancreatic intraepithelial neoplasms) with loss of *Oc1* protein and gene expression.^{30,31}

Very little is known about how *Oc1* regulates exocrine pancreas differentiation. Of the known direct *Oc1* targets in the pancreas (*Pdx1*, *Ngn3*, *MafA*, and *Hnf4 α*), most are endocrine-specific. Only *Pdx1* is expressed in the exocrine lineage (where it is expressed at a low level in subpopulations of acinar cells).^{10,28,32-39} *Oc1* directly binds to and regulates the *Hnf1 β* promoter in liver cholangiocytes,^{40,41} but it is unclear if this direct regulation also exists in the pancreatic ducts. The goal of the current study was to identify additional *Oc1* targets to better understand how *Oc1* regulates exocrine pancreas development. We found that loss of *Oc1* from the developing pancreatic epithelium results in severe exocrine dysplasia and altered gene expression consistent with impaired acinar cell differentiation. We also identified novel direct *Oc1* transcriptional targets in late-gestation pancreata using chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq).

Abbreviations used in this paper: ADM, acinar-to-ductal metaplasia; ChIP-Seq, chromatin immunoprecipitation followed by high-throughput sequencing; CK19, Cytokeratin 19; Cym, Chymosin; HH, Hedgehog; *Hnf1 β* , hepatocyte nuclear factor 1 β ; *Hnf6*, hepatocyte nuclear factor 6; *Ihh*, Indian hedgehog; *Inhba*, Inhibin, Beta A; *Mist1*, muscle, intestine, stomach transcription factor 1; MPC, multipotent pancreatic progenitor cell; *Nr5a2*, nuclear receptor subfamily 5, group A, member 2; *Oc1*, *Onecut1*; PDAC, pancreatic ductal adenocarcinoma; *Pdx1*, pancreatic and duodenal homeobox 1; *Ptch2*, Patched 2; *Ptf1a*, Pancreas transcription factor, 1a; RNA-Seq, RNA-sequencing; *Smo*, Smoothed; *Sox9*, SRY-related HMG-box 9; *Spink 1*, serine protease inhibitor Kazal type 1; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

 Most current article

© 2019 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2352-345X

<https://doi.org/10.1016/j.jcmgh.2019.02.004>

Results

Exocrine Pancreas Dysplasia in Embryonic and Neonatal *Oc1*^{Δpanc} Mice

We previously reported pancreatic hypoplasia in *Oc1*^{Δpanc} mice at e14.5 and exocrine dysplasia (ADM, fibrosis, periductal hemorrhaging) at 3 weeks of age.²⁷ These phenotypes demonstrated that *Oc1* has a role in regulating exocrine pancreas development; however, we wanted to determine when exocrine dysplasia first developed. We thus examined pancreata from *Oc1*^{Δpanc} mice just before birth at e18.5 and immediately after birth at postnatal day (P)2. It was evident that exocrine pancreas development was disrupted in *Oc1*^{Δpanc} pancreata at e18.5 as the pancreatic ducts were dilated, there was reduced acinar eosinophilia (Figure 1A and A'), and reduced acinar cell area (Figure 1E, Table 1) with a trend toward increased duct cell area (Figure 1G). These findings are consistent with global *Oc1*^{-/-} animals and our previous *Oc1*^{Δpanc} animals,^{26,27} and were even more pronounced at P2 (Figure 1B, B', F, and H, Table 1). Hematoxylin and eosin staining appeared to show increased fibrosis in both e18.5 and P2 *Oc1*^{Δpanc} pancreata, which we analyzed further with sirius red staining for collagen (Figure 1C, C', D, and D'). There was no statistically significant increase in pancreatic collagen at e18.5 (not shown), but there was a significant increase in pancreatic collagen at P2 (Figure 1I). Finally, cells expressing markers of both duct (Cytokeratin 19 [CK19]) and acini (amylase) could be detected in P2 *Oc1*^{Δpanc} pancreata (Figure 1J and K) consistent with ADM. Together, these data suggest an impairment in exocrine pancreas development and acinar cell identity.

The relative acinar cell area appeared to progressively decrease from e18.5 to P2, so we predicted that this reduction was caused by either increased acinar cell death or reduced acinar cell proliferation. Acinar cell proliferation was significantly increased at e18.5 (Figure 2A1, A2, and C) but not at P2 (Figure 2A3, A4, and C). Using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) labeling to detect apoptotic cells, we found that there was a significant increase in acinar cell death at both e18.5 and P2 in *Oc1*^{Δpanc} pancreata (Figure 2B and D). These findings demonstrate altered acinar cell population dynamics in *Oc1*^{Δpanc} samples.

Loss of *Oc1* From the Pancreatic Epithelium Results in Significant Gene Expression Changes During Development

To better understand the role of *Oc1* in regulating exocrine pancreas development, we used RNA-sequencing (RNA-Seq) to determine how loss of *Oc1* affects global gene expression. Total RNA was extracted from e18.5 exocrine-enriched samples. There was some variability in gene expression between biologic replicates (Figure 3A); however, many gene expression changes were consistent in *Oc1*^{Δpanc} samples. Of the 1842 affected genes, 1004 showed decreased expression and 838 had increased expression (Figure 3B). Among the 25 most significantly affected genes,

all had decreased expression except *Cym* (*chymosin*), a peptidase produced by gastric chief cells (Figure 3C). Many of the most significantly reduced genes were enzymes, such as amylase, trypsins, trypsin-like peptidases, or peptidase inhibitors that are normally expressed by pancreatic acinar cells (eg, *Amylase*, *Prss1*, *Prss3*, *Try4*, *Try10*, and *Spink1*) (Figure 3C). Accordingly, expression of acinar-lineage transcription factors, such as *Mist1*, *Gata4*, *Nr5a2*, and *Ptf1a*, was also decreased. Interestingly, *Onecut2* (*Oc2*) was 1 of the most significantly upregulated transcription factors. However, increased expression of this closely related factor clearly does not compensate for the loss of *Oc1*. Analysis of Biological Processes and Cellular Component categories revealed changes in genes associated with metabolic and developmental processes, membranes and vesicles, and nuclear factors (Figure 3D). The finding that acinar cells were disproportionately affected was further supported by gene ontology analysis using WebGestalt, which identified "Enzyme Inhibitor Activity" and "Endopeptidase Activity" as 2 of the 5 most significantly altered groups (Supplementary Tables 1–3). These findings imply that *Oc1* regulates expression of acinar cell genes that include other coregulating transcription factors and functional genes.

Another interesting finding was that "Wnt-Activated Receptor Activity," "Wnt-Protein Binding," and "Frizzled Binding" were identified as significantly altered pathways (Supplementary Tables 1–3). Examination of the components of these pathways demonstrated that the differentially expressed genes in *Oc1*^{Δpanc} samples were all upregulated. Wnt signaling is known to be an important mediator of exocrine pancreas development, but also acinar cell proliferation. It is possible that the enhanced acinar cell proliferation we observed in *Oc1*^{Δpanc} pancreata is caused by activation of the Wnt pathway. Another pathway with noticeable changes was HH signaling. *Ihh* (*Indian hedgehog*, ligand), *Ptch2* (*Patched2* HH receptor), *Smo* (*Smoothened*, patched target), *Gli1*, and *Gli2* (transcription factor effectors of HH signaling) were all upregulated. Of note, HH signaling must be specifically repressed in the foregut endoderm to allow for pancreas specification to take place and is inactive in normal exocrine pancreas homeostasis. It is thus interesting that expression of genes associated with other foregut endoderm-derived organs (*Cym*, *Irx3/4*, *Vill*, *Lgr5*) was significantly increased in *Oc1*^{Δpanc} samples. Collectively, these gene expression changes reveal that inactivation of *Oc1* in the developing pancreatic epithelium has a significant impact on the developing exocrine pancreas and potentially alters the identity of pancreatic cells.

Oc1 Inactivation in the Developing Pancreatic Epithelium Has Persistent Impacts on Postnatal Gene Expression

Analysis of RNA-Seq from exocrine-enriched samples at P2 also revealed significantly altered expression of 280 genes in *Oc1*^{Δpanc} samples despite some variability between biologic replicates (Figure 4A). Expression of 172 genes was downregulated, whereas 108 genes showed increased expression (Figure 4B). Approximately half of the genes




Figure 1. Exocrine dysplasia in *Oc1*^{Δpanc} pancreata. Representative hematoxylin and eosin images from e18.5 (A and A') and P2 (B and B') Control (A and B) and *Oc1*^{Δpanc} pancreata (A' and B'). Representative images of sirius red/fast green staining from e18.5 (C and C') and P2 (D and D') Control (C and D) and *Oc1*^{Δpanc} pancreata (C' and D'). e18.5 (n = 3 mice); P2 (n = 5 mice). Images captured at ×20. Amylase-positive area at e18.5 (E, n = 3 mice) and P2 (F, n = 5 mice); ratio of CK19+:Amylase+ area at e18.5 (G, n = 3 mice) and P2 (H, n = 5 mice). (I) Collagen-positive area at P2 (n = 5 mice). (J) Representative immunofluorescence images of amylase (red) and CK19 (green) in Control and *Oc1*^{Δpanc} pancreata at P2. Scale bar represents 100 μm. (K) Split channel of boxed area in J *Oc1*^{Δpanc}. ***P* ≤ .01, ****P* ≤ .001 by 2-tailed Student *t* test. H&E, hematoxylin and eosin.

Table 1. Quantification of Acinar Area

Stage	% Acinar area/pancreas area		P value
	Control	Oc1 ^{Δpanc}	
E18.5 (n = 3)	55.3% ± 6.1%	29.0% ± 13.2%	.0345
P2 (n = 5)	40.9% ± 6.4%	18.1% ± 7.1%	.0007

Data are presented as the mean ± standard deviation. P value derived from 2-tailed Student *t* tests.

altered in P2 Oc1^{Δpanc} samples are shared with e18.5 Oc1^{Δpanc} samples (Figure 4C). Several acinar cell functional genes were altered at both ages (eg, *Amylase*, *Cela1*, *Cpa1/2*, *Prss2*, and *Spink1*) suggesting that Oc1 directly regulates acinar cell function at both stages. Examination of the 25 most significantly altered genes (Figure 4D) supports previously published findings that Oc1 is required for endocrine cell differentiation.^{27,28}

WebGestalt analysis identified pathways associated with peptidase activity as 4 of the 5 most significantly affected pathways in the Biological Function category at P2 (Figure 4E, Supplementary Tables 4–6). These gene expression changes support the observed exocrine dysplasia in Oc1^{Δpanc} pancreata because dysplastic acinar cells have impaired peptidase expression. Similar to e18.5, components of the HH pathway were upregulated (*Ihh*, *Gli1*, *Ptch1*, and *Ptch2*) at P2 but components of the Wnt signaling pathway were largely unaffected. Interestingly, *Inhba* (Inhibin, Beta A), which has been associated with acinar cell dysplasia in pancreatic cancers,⁴² was 1 of the most significantly upregulated genes (5.788-fold). Its activity could contribute to the increased extracellular matrix deposition observed in Figure 1. *Oc2* was also upregulated at P2 (albeit to a lesser extent than at e18.5). In all, the RNA-Seq results from P2 Oc1^{Δpanc} samples confirm a continued decrease in expression of multiple acinar cell functional genes.

Identification of Direct Oc1 Targets in e18.5 Pancreata

To better understand how Oc1 directly regulates development of the exocrine pancreas we performed ChIP-Seq on whole pancreata from wildtype e18.5 mice. At this age, Oc1 is excluded from all hormone⁺ cells thereby allowing us to select for targets in the pancreatic ducts and acinar cells. There were approximately 7400 peaks identified, which were associated with 4962 genes. These peaks were enriched in the 5' untranslated regions and proximal promoters (<500 bp from transcription start sites) of the associated genes (Figure 5A). Of the 4962 genes associated with Oc1 binding peaks, 499 had altered gene expression in the e18.5 Oc1^{Δpanc} RNA-Seq indicating that Oc1 directly regulates transcription of these genes (Figure 5B). Motif analysis of our ChIP-Seq data also identified peaks of transcription factors that are known to associate with Oc1 (Figure 5C), suggesting that in acinar cells, Oc1 regulates gene expression cooperatively with other transcription factors.

Among the most noticeable direct Oc1 targets were *Ptf1a*, *Nr5a2*, and *Gata4* (Figure 5D–F), transcription factors that play vital roles in the specification, differentiation, and function of pancreatic acinar cells. All 3 of these factors had reduced expression in the Oc1^{Δpanc} RNA-Seq samples implying that Oc1 positively regulates their expression. A significant Oc1 binding peak was also identified in Area III of the *Pdx1* promoter (Figure 5G), the area that is known to promote nonendocrine expression of *Pdx1*.⁴³ Taken together, these data suggest that in acinar cells Oc1 functions, at least in part, through regulating other transcription factors. Oc1 also directly bound to regions associated with acinar cell functional genes, such as *Amylase*, *Prss1/2*, *Prss2*, *Pnlip*, *Pnliprp1/2*, and *Spink1* (not shown). Expression of each of these functional genes was decreased in Oc1^{Δpanc} pancreata. Thus, Oc1 directly regulates genes important for acinar cell identity and function and other acinar cell transcription factors.

We and others have demonstrated that loss of Oc1 from the developing pancreas results in ductal cysts, duct hyperplasia, and tortuous ducts.^{26,27} Thus, we predicted that the ChIP-Seq analysis would identify direct Oc1 targets that could be attributed to duct cells. The transcription factors *Hnf1β* and *FoxA2*, both of which are expressed in MPCs at early stages and later in the pancreatic ducts, were identified as direct Oc1 targets (Figure 5H and I). Other duct-specific genes, such as *Prox1* or *Sox9*, were not identified as targets in our analysis.

Although Oc1 functions as a transcriptional activator for many genes important in exocrine pancreas development, it also seems to function as a transcriptional repressor for genes associated with other endoderm-derived lineages. Both gastric and intestinal-associated genes were identified as direct Oc1 targets in the ChIP-Seq experiment and had increased expression the Oc1^{Δpanc} RNA-Seq. Most notable among these genes were the transcription factor *Irx3*, the G-protein coupled receptor *Lgr5*, and the cytoskeleton-related factor *Vill*.

Confirmation of Direct Oc1 Targets in e18.5 Pancreata

We next performed immunofluorescence imaging to validate the Oc1 targets identified by ChIP-Seq and RNA-Seq. For example, expression of *Mist1*, an acinar-lineage transcription factor, was found to be decreased by RNA-Seq analysis, but there were no Oc1 binding motifs associated with the *Mist1* gene (suggesting indirect regulation). To confirm the RNA-Seq data, we examined *Mist1* protein expression by immunolabeling. At e18.5 most acinar cells in Oc1^{Δpanc} pancreata have lower *Mist1* levels than cells in control pancreata (Figure 6A1 and A2). However, the average number of *Mist1*-positive cells was not altered (Figure 6C1). In contrast, by P2, both the level of *Mist1* protein and the number of *Mist1*-positive cells were decreased in Oc1^{Δpanc} (Figure 6A3, A4, and C2).

GATA4 is another acinar-lineage transcription factor. RNA-Seq analysis found that *Gata4* expression decreased in Oc1^{Δpanc} pancreata. Chip-Seq analysis further identified the




Figure 2. Altered acinar cell proliferation and death in $Oc1^{\Delta panc}$ pancreata. (A) Representative immunofluorescence images of amylase (red), Ki67 (green), and DAPI (blue) from e18.5 (A1 and A2) and P2 (A3 and A4) Control (A1 and A3) and $Oc1^{\Delta panc}$ (A2 and A4) pancreata. Images in the white dotted line box are shown at increased magnification at lower left. Arrows indicate Ki67-positive cells, arrowheads indicate Ki67-negative cells. (B) Representative immunofluorescence images of amylase (red), TUNEL (green), and DAPI (blue) from e18.5 (B1 and B2) and P2 (B3 and B4) Control (B1 and B3) and $Oc1^{\Delta panc}$ (B2 and B4) pancreata. (C) Quantification of acinar cell proliferation at e18.5 (C1) and P2 (C2). (D) Quantification of acinar cell apoptosis at e18.5 (D1) and P2 (D2). $n = 5$ mice for each group. $**P \leq .01$, $*P \leq .05$ by 2-tailed Student t test.

Gata4 gene as a direct target of Oc1. By immunolabeling, we found that at e18.5 there was increased heterogeneity of GATA4 expression in acinar cells of $Oc1^{\Delta panc}$ pancreata. A subpopulation of cells had lower GATA4 expression in $Oc1^{\Delta panc}$ (compare Figure 6B1 with B2). However, overall, using quantitative immunofluorescence we did not find a significant difference in the average GATA4 intensity between $Oc1^{\Delta panc}$ and control acinar cells (Figure 6D1). By P2, GATA4 intensity became significantly reduced in $Oc1^{\Delta panc}$ (Figure 6B3, B4, and D2). Putting our RNA-Seq, ChIP-Seq, and immunofluorescence data together, we propose that

Oc1 directly and positively regulates GATA4 expression. We also examined the expression of *Ptf1a*, another acinar lineage transcription factor, by immunofluorescence. Both our ChIP-Seq and RNA-Seq data suggest that Oc1 positively and directly regulates *Ptf1a*, but unfortunately, we cannot draw any firm conclusions at this time because of the variation in immunolabeling between samples (data not shown).

In addition to transcription factors, we also explored the expression level of the acinar cell functional protein Spink1, which was identified as a direct transcriptional target of Oc1. Spink1 is important to prevent the




Figure 3. Gene expression changes in e18.5 exocrine-enriched $Oc1^{\Delta panc}$ samples. (A) Heatmap of gene expression from RNA-Seq for each of 2 biologic replicates for Control (red bar at top) and $Oc1^{\Delta panc}$ (blue bar at top). Green indicates high expression; red indicates low expression. (B) Volcano plot of genes with differential expression in $Oc1^{\Delta panc}$ samples. Significant gene expression changes were determined by an FDR of 0.05 and \log_2 fold change of 1. Blue dots represent significantly reduced genes; red dots represent significantly increased genes with \log_2 fold change on the x-axis and adjusted P value on y-axis. (C) Plot of 25 most significantly altered genes. \log_2 fold change is plotted on the x-axis and gene names are plotted on the y-axis. (D) Bar graphs representing gene ontology analysis of biologic process, cellular component, and molecular function. See [Supplementary Tables 1–3](#) for further detail.

premature activation of trypsin to prevent autodigestion of the pancreas. At e18.5, Spink1 protein intensity was significantly reduced in $Oc1^{\Delta panc}$ (compare [Figure 7A](#) and [B](#), quantified in [E1](#)). We also found that in most acinar cells in control pancreata, Spink1 was uniformly distributed ([Figure 7A2](#) and [A3](#)), but in $Oc1^{\Delta panc}$ pancreata, there are high-intensity patches of Spink1 protein localized at the cortex of some cells ([Figure 7B2](#) and [B3](#)), indicating defects in intracellular localization of Spink1 in $Oc1^{\Delta panc}$ mutants. At P2, the disparity in Spink1 localization between control and $Oc1^{\Delta panc}$ pancreata becomes more pronounced. In most acinar cells in control pancreata, Spink1 is evenly distributed throughout the cytoplasm ([Figure 7C](#) and [F1](#)). However, in a subpopulation of cells in the mutants, Spink1 accumulates at the cell cortex (closely apposed to E-cadherin labeling) with almost no protein in the central cytoplasm ([Figure 7D3](#), [D4](#), and [F2](#)). Cells with cortical Spink1 often show additional defects in epithelial organization as indicated by E-cadherin immunolabeling, and are potentially undergoing ADM, as we have previously observed with loss of *Oc1*.²⁷ There remains a subpopulation of acinar cells with relatively normal cytoplasmic Spink1 distribution in the $Oc1^{\Delta panc}$ pancreata ([Figure 7D1](#)).

Conclusions

The current study provides the first report of direct transcriptional targets of the critical transcription factor OC1 (formerly known as Hnf6) in the developing exocrine pancreas. Together our data suggest that in the exocrine pancreas cells, Oc1 functions via at least 3 mechanisms: (1) direct and indirect regulation of acinar lineage transcription factors, (2) direct regulation of acinar cell functional genes, and (3) direct regulation of duct lineage genes. Our data also suggest that Oc1 cooperates with other endoderm transcription factors that bind near Oc1 target sequences to regulate exocrine gene expression. Our results also solidify a role for Oc1 in establishing pancreas identity, because expression of posterior foregut genes normally restricted from the pancreas anlagen was elevated in the absence of Oc1.

Loss of *Oc1* from the developing pancreatic epithelium results in impaired development of the pancreatic ducts and acinar cells.^{26,27} These findings, paired with the findings that OC1 expression is lost from acinar cells in human PDAC,^{30,31} suggest that Oc1 has a role in regulation of acinar cell identity. Here we show that inactivation of *Oc1* during pancreas development results in embryonic acinar cell dysplasia that becomes progressively more severe after birth. These findings are consistent with other models of




Figure 4. Gene expression changes in P2 exocrine-enriched *Oc1^{Δpanc}* samples. (A) Heatmap of gene expression from RNA-Seq for each of 2 biologic replicates for Control (red bar at top) and *Oc1^{Δpanc}* (blue bar at top). Green indicates high expression; red indicates low expression. (B) Volcano plot of genes with differential expression in *Oc1^{Δpanc}* samples. Significant gene expression changes were determined by an FDR of 0.05 and log₂ fold change of 1. Blue dots represent significantly reduced genes; red dots represent significantly increased genes with log₂ fold change on the x-axis and adjusted P value on y-axis. (C) Venn diagram illustrating overlapping gene expression changes at e18.5 and P2. (D) Plot of 25 most significantly altered genes. Log₂ fold change is plotted on the x-axis and gene names are plotted on the y-axis. (E) Bar graphs representing gene ontology analysis of biologic process, cellular component, and molecular function. See [Supplementary Tables 4–6](#) for further detail.

impaired acinar cell differentiation, such as inactivation of *Nr5a2*, which results in acinar hypoplasia and disrupted acinus morphology.¹³ The *Oc1^{Δpanc}* phenotype is distinct from knock-out models of acinar cell transcription factors, such as *Mist1* or *Gata6*, which are dispensable for acinar cell differentiation, but vital for postnatal acinar cell identity.^{16,44–48} Indeed, both *Mist1* and *Gata6* embryonic knockout models have little to no phenotype before birth. Of note, GATA4 and GATA6 have partially redundant roles in pancreas organogenesis and inactivation of both factors

during embryogenesis has severe consequences for both endocrine and exocrine pancreas development.^{49–51} Thus, morphology of the *Oc1^{Δpanc}* pancreas is more similar to that of knock-out models for factors regulating acinar cell differentiation (*Nr5a2*) than acinar cell identity and function (*Mist1*, *Gata6*) suggesting that *Oc1* contributes to regulation of acinar cell differentiation.

The reduction in acinar cell area in *Oc1* mutants likely results from a combination of reduced specification and differentiation from MPCs as well as increased acinar cell




Figure 5. Identification of direct Oc1 targets in e18.5 pancreata. (A) Genomic regions with enrichment of reads in Oc1 ChIP-Seq samples. Yellow indicates higher incidence of reads. (B) Venn diagram illustrating overlap of genes with altered expression in e18.5 *Oc1*^{Δpanc} RNA-Seq samples (red) with genes associated with Oc1 binding peaks in e18.5 ChIP-Seq samples (blue). (C) Motif analysis of other transcription factor binding sites identified near Oc1 binding sites in Oc1 targets. (D–I) Sashimi plots of Oc1 binding peaks. Each track (red or light blue peak build-up) shows alignments from an individual biologic replicate. Gene coding regions are represented as darker blue annotations at the bottom of each plot. (D) *Ptf1a*. (E) *Nr5a2*. (F) *Gata4*. (G) *Pdx1*. (H) *Hnf1β*. (I) *FoxA2*.

apoptosis. Our finding that acinar cell death was increased in *Oc1*^{Δpanc} pancreata was not surprising given the severely disrupted acinar compartment; however, the finding that acinar cell proliferation was increased at e18.5 was unexpected. Increased proliferation to compensate for reduced specification or differentiation is not unprecedented in the pancreas. We have previously demonstrated that such a process can occur in β cells⁵² and others have shown that epithelial cells of primitive ducts can proliferate in order to produce more endocrine progenitors.⁵³ Additionally, acinar cells show increased proliferation following injury in adult pancreata,^{54,55} so it is possible that such a mechanism is also functioning in *Oc1*^{Δpanc} acinar cells at e18.5 to

compensate for the reduced acinar cell area. Postnatal acinar cell proliferation is partially regulated by Wnt signaling.^{54–56} Our RNA-Seq results indicated that e18.5 *Oc1*^{Δpanc} pancreata had increased expression of multiple components of the Wnt pathway, so it seems likely that Wnt-activation is closely connected with the observed increase in proliferation. Of note, *Wnt7b* (which contributes to regulation of pancreas morphogenesis⁵⁷) was identified as a direct target of Oc1 in our ChIP-Seq analysis and also showed increased mRNA expression, likely caused by direct loss of *Oc1* activity.

Our RNA-Seq results revealed decreased expression of many important acinar cell genes including regulatory




Figure 6. (A) Representative immunohistochemistry images of Mist1 (brown) from e18.5 (A1 and A2) and P2 (A3 and A4) Control (A1 and A3) and $Oc1^{\Delta panc}$ pancreata (A2 and A4). Arrows show cells with high Mist1 expression; arrowheads show cells with low Mist1 expression. (B) Representative immunofluorescence images of Gata4 (green) and DAPI (red) from e18.5 (B1 and B2) and P2 (B3 and B4) Control (B1 and B3) and $Oc1^{\Delta panc}$ pancreata (B2 and B4). (C) Quantification of the number of Mist1-positive cells at e18.5 (C1) and P2 (C2). (D) Quantification of Gata4 intensity at e18.5 (D1) and P2 (D2). n = 3 mice for each group. * $P \leq .05$ by 2-tailed Student *t* test.




Figure 7. Representative immunofluorescence images of Spink1 (red), E-cadherin (green), and DAPI (blue) from e18.5 (A and B) and P2 (C and D) Control (A and C) and Oc1 Δ panc pancreata (B and D). Boxed region in A1 is shown at higher magnification in A2 and A3. Boxed region in B1 is shown at higher magnification in B2 and B3. Boxed region in C1 is shown at higher magnification in C2 and C3. White dotted line in C2 indicates the long axis of the cell used for scan in F1. Boxed region in D1 is shown at higher magnification in D2. Two boxed regions in D2 are further zoomed in D3 and D4 or D5 and D6. White dotted line in D5 indicates the long axis of the cell used for scan in F2. (B) Arrows indicate high intensity Spink1 patches. (D) Arrows indicate Spink1 protein accumulated at the cell cortex. (E) Quantification of Spink1 intensity at e18.5 (E1) and P2 (E2). $n = 3$ mice for each group. $**P \leq .001$ by 2-tailed Student t test. (F) Intensity line scan across the long axis of the cell indicated by the white lines in C2 (F1, Control) and D5 (F2, Oc1 Δ panc).

transcription factors (*Ptf1a*, *Nr5a2*, *Mist1*) and functional genes (*Prss1/2*, *Spink1*, *Amylase*). These findings suggest an impairment in acinar cell identity and are consistent with the observed morphologic changes. Additionally, we

detected increased expression of genes associated with other endoderm-derived organs, such as *Cym*, *Vill*, *Irx3/4*, and *Lgr5* as well as increased expression of components of the HH signaling pathway. Expression of these genes could

indicate a misallocation of pancreatic cells to alternative endoderm fates. Although histologic analyses did not reveal any obvious morphologic changes consistent with other endodermal derivatives, it is possible that cells in *Oc1*^{Δpanc} pancreata express a complement of genes associated with overlapping cell fate phenotypes. This possibility suggests that *Oc1* functions in the pancreatic epithelium in part to repress specification of nonpancreatic foregut endoderm fates.

Notably, the observed gene expression changes were still significant in spite of the variability between samples. The sample variability may be caused by the following: (1) inclusion of some endocrine cells in control samples, (2) the stress of dissociating the tissue and the subsequent selection of exocrine-enriched samples, and (3) “survival bias” whereby mutant acinar cells showing the strongest phenotype are less likely to survive the tissue dissociation procedure. The presence of activated digestive enzymes likely contributed to the greater RNA-Seq variability observed at P2 compared with e18.5. Yet, consistent and significant gene expression changes were still detected in our biologic replicates providing support for the veracity of these findings.

We were surprised that few of the genes affected in *Oc1*^{Δpanc} samples were associated with pancreatic ducts, and it is unlikely that duct cells were not significantly affected by loss of *Oc1*. Duct cells only constitute a small percentage of pancreatic cells and thus the changes in expression could have been masked by the changes in acinar cell gene expression. In spite of the limited ability to detect these targets, *FoxA2* and *Hnf1β* were identified as direct *Oc1* targets. These findings are consistent with *Oc1* directly regulating these 2 genes in hepatocytes and cholangiocytes.^{35,58-61} Sorting of labeled pancreatic duct cells would likely yield additional gene expression changes and *Oc1* targets associated with the ductal phenotype.

The identification of direct *Oc1* targets in e18.5 pancreas provides novel information about the mechanism of how *Oc1* regulates gene expression in the developing pancreas. These results demonstrate that *Oc1* functions to promote expression of select acinar cell regulatory factors, such as *Ptf1a*, *Nr5a2*, and *Pdx1*. Notably, each of these factors is necessary for specification and differentiation of acinar cells during pancreas development. *Oc1* did not bind to any known regulatory sequence of the *Mist1* gene even though its expression was reduced in *Oc1*^{Δpanc} samples, suggesting an indirect mechanism of regulation. Additionally, our studies revealed that *Oc1* directly binds Area III of the *Pdx1* promoter, suggesting a nonendocrine role for regulation of *Pdx1* by *Oc1*. *Pdx1* is indeed expressed in acinar cells, albeit at low levels, so we were surprised to find that *Pdx1* gene expression was not significantly reduced in our RNA-Seq analysis. It is possible that *Oc1* does not actively regulate *Pdx1* gene expression at this time in spite of its binding to Area III. Interestingly, *Gata4* was identified as a direct *Oc1* target but not *Gata6*. As noted above, these 2 factors have partially redundant roles in pancreas development, so it is possible that *Oc1* contributes to the more nuanced regulation of these 2 factors. *Oc1* also directly regulates acinar cell functional genes, such as *Prss1/2*, *Amylase*, and *Spink1*.

These findings demonstrate that *Oc1* has a previously unknown role in actively regulating acinar cell function through promoting expression of select digestive enzymes.

The accumulation of *Spink1* at the cell cortex may be a consequence of the defects of cell polarity in *Oc1*^{Δpanc}. Under normal conditions, *Spink1* is packaged together with trypsin into the zymogen granules and then secreted from apical surface of acinar cells in a tightly regulated manner.^{62,63} Our previous work has demonstrated that *Oc1* deletion leads to defects of cell polarity.²⁷ It is possible that when acinar cell polarity was disrupted, *Spink1* failed to be secreted properly. However, the intracellular transportation machinery is still transporting *Spink1* toward the cortex, leading to the accumulation of *Spink1* underneath the cortex. Overall, our immunofluorescence analysis shows stronger defects in protein expression and localization at P2 than e18.5. The stronger phenotype at P2 likely reflects the cumulative defects of losing *Oc1* at earlier stages.

Both ChIP-Seq and RNA-Seq provide a starting point for understanding gene function. However, because of biologic complexity, candidate pathways/genes identified by such analysis need to be further validated at the protein expression level. Our immunofluorescence analysis found that *Gata4*, *Mist1* expression start to decrease at E18.5, and the defects deteriorate at P2, suggesting *Oc1* regulates acinar cell function through these transcription factors. Among the functional genes, we are particularly interested in *Spink1* (also called *Spink3* in mouse). Our ChIP-Seq shows *Spink1* is a direct target of *Oc1*. *Spink1* is important to prevent the self-digestion of the pancreas by the premature activation of trypsin. It was shown that *Spink1* prevents serine protease-dependent cell apoptosis.⁶⁴ Losing *Spink1* in mice directly leads to autophagic cell death of acinar cells.⁶⁵ Therefore, *Oc1* might regulate acinar cell survival through *Spink1*.

Together, the current findings suggest that *Oc1* has an important role in regulating differentiation and identity of acinar cells. However, it remains possible that some of the acinar dysplasia phenotypes observed in *Oc1*^{Δpanc} samples involve cell-nonautonomous effects of *Oc1* inactivation in the ducts. Defects in the pancreatic ducts have been previously demonstrated to have secondary effects on the acinar cells^{66,67} and inactivation of *Oc1* in ducts results in a phenotype very similar to the *Oc1*^{Δpanc} model described here.²⁹ This group has also shown that overexpression of *Oc1* in acinar cells can cause ADM and loss of acinar cell identity.⁶⁸ It is possible that *Oc1* dosage is an important determining factor for acinar cell identity versus duct cell identity. The current work provides a foundation for future work into the mechanisms whereby *Oc1* regulates duct and acinar cell development.

Methods

Animals

Oc1 floxed mice are described elsewhere.²⁷ The *Pdx1-Cre* transgenic mice are described elsewhere.⁶⁹ Control mice carried the *Pdx1-Cre* transgene; *Oc1*^{Δpanc} mice had the genotype *Oc1*^{fl/fl};*Pdx1-Cre*. All mice were on a mixed genetic

background. Mice were maintained on a 12-hour light/dark cycle and provided food and water *ad libitum*. All experiments involving mice were approved by the Institutional Animal Care and Use Committee of Vanderbilt University Medical Center. All authors had access to the study data and reviewed and approved the final manuscript.

Tissue Preparation and Imaging

Digestive organs were fixed for 4 hours in 4% paraformaldehyde at room temperature, dehydrated, cleared in xylenes, and embedded in paraffin. Paraffin-embedded tissues were cut at 5 μm , deparaffinized in xylene, and rehydrated in water. Fluorescent and bright field images were captured using either an Olympus BX41 microscope, the Aperio ScanScope microscope and slide scanner (Vista, CA), or a Nikon spinning disk confocal driven by Nikon Elements or Nikon 600 with MagnaFire software (Optronics Engineering, Goleta, CA). Hematoxylin and eosin staining was performed as described elsewhere.⁷⁰ For sirius red/fast green staining, slides were incubated 1 hour in the staining solution (1 mg/ml Direct Red 80 [Sigma, St. Louis, MO], 1 mg/ml Fast Green [Sigma] in 3% picric acid solution), washed 2 \times 5' in acidified water (1% glacial acetic acid solution), dehydrated, and mounted with a xylene-based mounting medium.

Immunofluorescence

For embryonic and postnatal analyses, tissue sections approximately 150 μm apart (2–4 per animal) were analyzed. Primary antibodies were: rat α -CK19 (TROMA III; Developmental Studies Hybridoma Bank, Iowa City, IA; 1:500), goat α -amylase (Santa Cruz Biotechnologies, Dallas, TX; 1:500), rabbit α -Ki67 (Jackson Laboratories, West Grove, PA; 1:500), mouse α -GATA4 (Invitrogen, Carlsbad, CA; 1:500), rabbit α -Spink1 (LSBio, Seattle, WA; 1:100), and rabbit α -Mist1 (a gift from Dr Stephen Konieczny, Purdue University). TUNEL labeling was carried out using the ApoAlert DNA Fragmentation Assay Kit (Clontech, Mountain View, CA) following the manufacturer's protocol. Species-specific secondary antibodies were conjugated to Cy2, Cy3, or Cy5 and diluted 1:500. Labeling with the α -CK19 antibody required incubation with 0.2 mg/mL proteinase K. Labeling with the α -Ki67 antibody required heat-mediated antigen retrieval in a 10-mM sodium citrate buffer.

RNA Acquisition and Sequencing

Pancreata were dissected from e18.5 and P2 mice, dissociated with collagenase, and exocrine-enriched samples (islets excluded) were collected for RNA extraction in 500 μl Trizol reagent (ThermoFisher, Waltham, MA). Total RNA was generated from 2 animals per genotype. RNA was isolated using the RNeasy Micro kit (Qiagen, Germantown, MD) according to manufacturer's instructions. RNA concentration and integrity were assessed using a ND-1000 Spectrophotometer (NanoDrop) and the 2100 Electrophoresis Bioanalyzer (Agilent, Santa Clara, CA) at Vanderbilt Technologies for Advanced Genomics (VANTAGE) Core. Libraries of 100-bp fragments were generated for each sample by the VANTAGE Core. Libraries were pair-end

sequenced to a depth of 50 million reads on an Illumina HiSeq2000 (San Diego, CA). Sequences were aligned to the mm10 genome and DESeq2⁷¹ was used to determine differentially expressed genes using an FDR cutoff of 0.05 and log₂-fold change of 1 by the Vanderbilt Technologies^{72,73} was used to perform gene ontology analysis.

Chromatin Immunoprecipitation Preparation and Sequencing

For each of 2 biologic replicates, 3–4 e18.5 pancreata were combined and minced with fine scissors. Samples were fixed 10 minutes in 1.11% formaldehyde at room temperature and reactions quenched by adding glycine to a final concentration of 0.125 M. Samples were homogenized by hand with plastic pestles. Chromatin was sheared with a Diagenode Bioruptor for a total of 22.5 minutes to an average length of 300 bp. ChIP was performed with 200 μg of DNA and 10 μg of Oc1 antibody (Rabbit α -Hnf6, Santa Cruz Biotechnology sc-13050) and Protein A/G plus agarose beads (Santa Cruz Biotechnology). DNA was purified from each reaction with the MinElute PCR Purification kit (Qiagen). Libraries were generated by HudsonAlpha Institute for Biotechnology (Huntsville, AL). Libraries were pair-end sequenced at 50 bp on an Illumina HiSeq 2000 platform to a depth of 50 million reads. Sequences were aligned to the mm10 genome and peaks were called using MACS2 software with an FDR of 0.05 by VANGARD.

Data Analysis and Statistics

To quantify acinar cell area, pancreas tissue was stained with hematoxylin and eosin. Colors were separated using a customized algorithm in Python. Image J particle analysis was used to quantify the whole pancreas area and acinar area after color separation. For immunofluorescence labeling shown in Figures 1, 2, 6, and 7, a total of 3–5 mice were analyzed for each group. For each mouse, 2–4 tissue sections approximately 150 μm apart were analyzed. The average value for each mouse was then used to compare between different groups. Image analysis was performed either with ImageScope software from the Aperio suite (Vista, CA) or with Image J. Image contrast, brightness, and gamma were adjusted equally for each image to bring out the details of the images for the purpose of illustration. Data are presented as the mean \pm standard deviation. Statistical analyses were performed as 2-tailed Student *t* tests using GraphPad Prism 6 software.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin* 2017;67:7–30.
2. Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JPt, Pan FC, Akiyama H, Wright CV, Jensen K, Hebrok M, Sander M. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012;22:737–750.
3. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic

- ductal adenocarcinoma. *Nat Rev Cancer* 2010; 10:683–695.
4. Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, Melton DA. A multipotent progenitor domain guides pancreatic organogenesis. *Dev Cell* 2007;13:103–114.
 5. Gao N, LeLay J, Vatamaniuk MZ, Rieck S, Friedman JR, Kaestner KH. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. *Genes Dev* 2008;22:3435–3448.
 6. Wu KL, Gannon M, Peshavaria M, Offield MF, Henderson E, Ray M, Marks A, Gamer LW, Wright CV, Stein R. Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. *Mol Cell Biol* 1997;17:6002–6013.
 7. Burlison JS, Long Q, Fujitani Y, Wright CV, Magnuson MA. Pdx-1 and Ptf1a concurrently determine fate specification of pancreatic multipotent progenitor cells. *Dev Biol* 2008;316:74–86.
 8. Thompson N, Gesina E, Scheinert P, Bucher P, Grapin-Botton A. RNA profiling and chromatin immunoprecipitation-sequencing reveal that PTF1a stabilizes pancreas progenitor identity via the control of MNX1/HLXB9 and a network of other transcription factors. *Mol Cell Biol* 2012;32:1189–1199.
 9. Krah NM, De La OJ, Swift GH, Hoang CQ, Willet SG, Chen Pan F, Cash GM, Bronner MP, Wright CV, MacDonald RJ, Murtaugh LC. The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. *eLife* 2015;4.
 10. Pan FC, Bankaitis ED, Boyer D, Xu X, Van de Castelee M, Magnuson MA, Heimberg H, Wright CV. Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury-induced facultative restoration. *Development* 2013;140:751–764.
 11. Hoang CQ, Hale MA, Azevedo-Pouly AC, Elsassner HP, Deering TG, Willet SG, Pan FC, Magnuson MA, Wright CV, Swift GH, MacDonald RJ. Transcriptional maintenance of pancreatic acinar identity, differentiation, and homeostasis by PTF1A. *Mol Cell Biol* 2016; 36:3033–3047.
 12. von Figura G, Morris JPt, Wright CV, Hebrok M. Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation. *Gut* 2014;63:656–664.
 13. Hale MA, Swift GH, Hoang CQ, Deering TG, Masui T, Lee YK, Xue J, MacDonald RJ. The nuclear hormone receptor family member NR5A2 controls aspects of multipotent progenitor cell formation and acinar differentiation during pancreatic organogenesis. *Development* 2014;141:3123–3133.
 14. Nissim S, Weeks O, Talbot JC, Hedgepeth JW, Wucherpennig J, Schatzman-Bone S, Swinburne I, Cortes M, Alexa K, Megason S, North TE, Amacher SL, Goessling W. Iterative use of nuclear receptor Nr5a2 regulates multiple stages of liver and pancreas development. *Dev Biol* 2016;418:108–123.
 15. Lemercier C, To RQ, Swanson BJ, Lyons GE, Konieczny SF. Mist1: a novel basic helix-loop-helix transcription factor exhibits a developmentally regulated expression pattern. *Dev Biol* 1997;182:101–113.
 16. Pin CL, Bonvissuto AC, Konieczny SF. Mist1 expression is a common link among serous exocrine cells exhibiting regulated exocytosis. *Anat Rec* 2000; 259:157–167.
 17. Pin CL, Rukstalis JM, Johnson C, Konieczny SF. The bHLH transcription factor Mist1 is required to maintain exocrine pancreas cell organization and acinar cell identity. *J Cell Biol* 2001;155:519–530.
 18. De Vas MG, Kopp JL, Heliot C, Sander M, Cereghini S, Haumaitre C. Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors. *Development* 2015;142:871–882.
 19. Kopp JL, Dubois CL, Schaffer AE, Hao E, Shih HP, Seymour PA, Ma J, Sander M. Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. *Development* 2011;138:653–665.
 20. Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. Sox9 coordinates a transcriptional network in pancreatic progenitor cells. *Proc Natl Acad Sci U S A* 2007;104:10500–10505.
 21. Maestro MA, Boj SF, Luco RF, Pierreux CE, Cabedo J, Servitja JM, German MS, Rousseau GG, Lemaigre FP, Ferrer J. Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas. *Hum Mol Genet* 2003; 12:3307–3314.
 22. Maestro MA, Cardalda C, Boj SF, Luco RF, Servitja JM, Ferrer J. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. *Endocr Dev* 2007;12:33–45.
 23. Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, Scherer G, Sander M. SOX9 is required for maintenance of the pancreatic progenitor cell pool. *Proc Natl Acad Sci U S A* 2007;104:1865–1870.
 24. Shih HP, Kopp JL, Sandhu M, Dubois CL, Seymour PA, Grapin-Botton A, Sander M. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. *Development* 2012;139:2488–2499.
 25. Shih HP, Seymour PA, Patel NA, Xie R, Wang A, Liu PP, Yeo GW, Magnuson MA, Sander M. A gene regulatory network cooperatively controlled by Pdx1 and Sox9 governs lineage allocation of foregut progenitor cells. *Cell Rep* 2015;13:326–336.
 26. Pierreux CE, Poll AV, Kemp CR, Clotman F, Maestro MA, Cordi S, Ferrer J, Leyns L, Rousseau GG, Lemaigre FP. The transcription factor hepatocyte nuclear factor-6 controls the development of pancreatic ducts in the mouse. *Gastroenterology* 2006;130:532–541.
 27. Zhang H, Ables ET, Pope CF, Washington MK, Hipkens S, Means AL, Path G, Seufert J, Costa RH, Leiter AB, Magnuson MA, Gannon M. Multiple, temporal-specific roles for HNF6 in pancreatic endocrine and ductal differentiation. *Mech Dev* 2009; 126:958–973.
 28. Jacquemin P, Durviaux SM, Jensen J, Godfraind C, Gradwohl G, Guillemot F, Madsen OD, Carmeliet P, Dewerchin M, Collen D, Rousseau GG, Lemaigre FP. Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and

- controls expression of the proendocrine gene *ngn3*. *Mol Cell Biol* 2000;20:4445–4454.
29. Augereau C, Collet L, Vargiu P, Guerra C, Ortega S, Lemaigre FP, Jacquemin P. Chronic pancreatitis and lipomatosis are associated with defective function of ciliary genes in pancreatic ductal cells. *Hum Mol Genet* 2016;25:5017–5026.
 30. Jiang X, Zhang W, Kayed H, Zheng P, Giese NA, Friess H, Kleeff J. Loss of *ONECUT1* expression in human pancreatic cancer cells. *Oncol Rep* 2008;19:157–163.
 31. Pekala KR, Ma X, Kropp PA, Petersen CP, Hudgens CW, Chung CH, Shi C, Merchant NB, Maitra A, Means AL, Gannon MA. Loss of *HNF6* expression correlates with human pancreatic cancer progression. *Lab Invest* 2014;94:517–527.
 32. Briancon N, Bailly A, Clotman F, Jacquemin P, Lemaigre FP, Weiss MC. Expression of the alpha7 isoform of hepatocyte nuclear factor (HNF) 4 is activated by *HNF6/OC-2* and *HNF1* and repressed by *HNF4alpha1* in the liver. *J Biol Chem* 2004;279:33398–33408.
 33. Gannon M, Ray MK, Van Zee K, Rausa F, Costa RH, Wright CV. Persistent expression of *HNF6* in islet endocrine cells causes disrupted islet architecture and loss of beta cell function. *Development* 2000;127:2883–2895.
 34. Jacquemin P, Lemaigre FP, Rousseau GG. The *Onecut* transcription factor *HNF-6 (OC-1)* is required for timely specification of the pancreas and acts upstream of *Pdx-1* in the specification cascade. *Dev Biol* 2003;258:105–116.
 35. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA. Control of pancreas and liver gene expression by *HNF* transcription factors. *Science* 2004;303:1378–1381.
 36. Oliver-Krasinski JM, Kasner MT, Yang J, Crutchlow MF, Rustgi AK, Kaestner KH, Stoffers DA. The diabetes gene *Pdx1* regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. *J Clin Invest* 2009;119:1888–1898.
 37. Roy N, Takeuchi KK, Ruggeri JM, Bailey P, Chang D, Li J, Leonhardt L, Puri S, Hoffman MT, Gao S, Halbrook CJ, Song Y, Ljungman M, Malik S, Wright CV, Dawson DW, Biankin AV, Hebrok M, Crawford HC. *PDX1* dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. *Genes Dev* 2016;30:2669–2683.
 38. Tweedie E, Artner I, Crawford L, Poffenberger G, Thorens B, Stein R, Powers AC, Gannon M. Maintenance of hepatic nuclear factor 6 in postnatal islets impairs terminal differentiation and function of beta-cells. *Diabetes* 2006;55:3264–3270.
 39. Yamamoto K, Matsuoka TA, Kawashima S, Takebe S, Kubo F, Miyatsuka T, Kaneto H, Shimomura I. A novel function of *OneCut1* protein as a negative regulator of *MafA* gene expression. *J Biol Chem* 2013;288:21648–21658.
 40. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, Roskams T, Rousseau GG, Lemaigre FP. The *onecut* transcription factor *HNF6* is required for normal development of the biliary tract. *Development* 2002;129:1819–1828.
 41. Poll AV, Pierreux CE, Lokmane L, Haumaitre C, Achouri Y, Jacquemin P, Rousseau GG, Cereghini S, Lemaigre FP. A *vHNF1/TCF2-HNF6* cascade regulates the transcription factor network that controls generation of pancreatic precursor cells. *Diabetes* 2006;55:61–69.
 42. Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K. *Activin* signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. *Cancer Lett* 2015;356(2 Pt B):819–827.
 43. Wiebe PO, Kormish JD, Roper VT, Fujitani Y, Alston NI, Zaret KS, Wright CV, Stein RW, Gannon M. *Ptf1a* binds to and activates area III, a highly conserved region of the *Pdx1* promoter that mediates early pancreas-wide *Pdx1* expression. *Mol Cell Biol* 2007;27:4093–4104.
 44. Jiang M, Azevedo-Pouly A, Deering TG, Hoang CQ, DiRenzo D, Hess DA, Konieczny SF, Swift GH, MacDonald RJ. *MIST1* and *PTF1* collaborate in feed-forward regulatory loops that maintain the pancreatic acinar phenotype in adult mice. *Mol Cell Biol* 2016;36:2945–2955.
 45. Martinelli P, Canamero M, del Pozo N, Madriles F, Zapata A, Real FX. *Gata6* is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice. *Gut* 2013;62:1481–1488.
 46. Martinelli P, Madriles F, Canamero M, Pau EC, Pozo ND, Guerra C, Real FX. The acinar regulator *Gata6* suppresses *KrasG12V*-driven pancreatic tumorigenesis in mice. *Gut* 2016;65:476–486.
 47. Shi G, Zhu L, Sun Y, Bettencourt R, Damsz B, Hruban RH, Konieczny SF. Loss of the acinar-restricted transcription factor *Mist1* accelerates *Kras*-induced pancreatic intraepithelial neoplasia. *Gastroenterology* 2009;136:1368–1378.
 48. Zhu L, Tran T, Rukstalis JM, Sun P, Damsz B, Konieczny SF. Inhibition of *Mist1* homodimer formation induces pancreatic acinar-to-ductal metaplasia. *Mol Cell Biol* 2004;24:2673–2681.
 49. Xuan S, Borok M, Duncan S, Sussel L. Transcription factors *Gata4* and *Gata6* play compensatory roles in pancreas development. *Developmental Biology* 2011;356:240.
 50. Xuan S, Borok MJ, Decker KJ, Battle MA, Duncan SA, Hale MA, Macdonald RJ, Sussel L. Pancreas-specific deletion of mouse *Gata4* and *Gata6* causes pancreatic agenesis. *J Clin Invest* 2012;122:3516–3528.
 51. Xuan S, Sussel L. *GATA4* and *GATA6* regulate pancreatic endoderm identity through inhibition of hedgehog signaling. *Development* 2016;143:780–786.
 52. Henley KD, Stanescu DE, Kropp PA, Wright CV, Won KJ, Stoffers DA, Gannon M. Threshold-Dependent cooperativity of *Pdx1* and *Oc1* in pancreatic progenitors establishes competency for endocrine differentiation and beta-cell function. *Cell Rep* 2016;15:2637–2650.
 53. Nishimura W, Kapoor A, El Khattabi I, Jin W, Yasuda K, Bonner-Weir S, Sharma A. Compensatory response by

- late embryonic tubular epithelium to the reduction in pancreatic progenitors. *PLoS One* 2015;10:e0142286.
54. Keefe MD, Wang H, De La OJ, Khan A, Firpo MA, Murtaugh LC. Beta-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in mice. *Dis Model Mech* 2012;5:503–514.
 55. Murtaugh LC, Keefe MD. Regeneration and repair of the exocrine pancreas. *Ann Rev Physiol* 2015;77:229–249.
 56. Heiser PW, Lau J, Taketo MM, Herrera PL, Hebrok M. Stabilization of beta-catenin impacts pancreas growth. *Development* 2006;133:2023–2032.
 57. Afelik S, Pool B, Schmerr M, Penton C, Jensen J. Wnt7b is required for epithelial progenitor growth and operates during epithelial-to-mesenchymal signaling in pancreatic development. *Dev Biol* 2015;399:204–217.
 58. Cheng W, Guo L, Zhang Z, Soo HM, Wen C, Wu W, Peng J. HNF factors form a network to regulate liver-enriched genes in zebrafish. *Dev Biol* 2006;294:482–496.
 59. Matthews RP, Lorent K, Russo P, Pack M. The zebrafish onecut gene *hnf-6* functions in an evolutionarily conserved genetic pathway that regulates vertebrate biliary development. *Dev Biol* 2004;274:245–259.
 60. Rausa F, Samadani U, Ye H, Lim L, Fletcher CF, Jenkins NA, Copeland NG, Costa RH. The cut-homeodomain transcriptional activator HNF-6 is coexpressed with its target gene HNF-3 beta in the developing murine liver and pancreas. *Dev Biol* 1997;192:228–246.
 61. Rubins NE, Friedman JR, Le PP, Zhang L, Brestelli J, Kaestner KH. Transcriptional networks in the liver: hepatocyte nuclear factor 6 function is largely independent of Foxa2. *Mol Cell Biol* 2005;25:7069–7077.
 62. Castle JD. Sorting and secretory pathways in exocrine cells. *Am J Respir Cell Mol Biol* 1990;2:119–126.
 63. Wang G-P, Xu C-S. Pancreatic secretory trypsin inhibitor: more than a trypsin inhibitor. *World J Gastrointest Pathophysiol* 2010;1:85–90.
 64. Lu X, Lamontagne J, Lu F, Block TM. Tumor-associated protein SPIK/TATI suppresses serine protease dependent cell apoptosis. *Apoptosis* 2008;13:483–494.
 65. Ohmuraya M, Hirota M, Araki M, Mizushima N, Matsui M, Mizumoto T, Haruna K, Kume S, Takeya M, Ogawa M, Araki K, Yamamura Ki. Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3—deficient mice. *Gastroenterology* 2005;129:696–705.
 66. Freedman SD, Kern HF, Scheele GA. Pancreatic acinar cell dysfunction in CFTR(-/-) mice is associated with impairments in luminal pH and endocytosis. *Gastroenterology* 2001;121:950–957.
 67. Golson ML, Loomes KM, Oakey R, Kaestner KH. Ductal malformation and pancreatitis in mice caused by conditional Jag1 deletion. *Gastroenterology* 2009;136:1761–1771.
 68. Prevot PP, Simion A, Grimont A, Colletti M, Khalaleh A, Van den Steen G, Sempoux C, Xu X, Roelants V, Hald J, Bertrand L, Heimberg H, Konieczny SF, Dor Y, Lemaigre FP, Jacquemin P. Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. *Gut* 2012;61:1723–1732.
 69. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowry AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003;4:437–450.
 70. Riley KG, Pasek RC, Maulis MF, Dunn JC, Bolus WR, Kendall PL, Hasty AH, Gannon M. Macrophages are essential for CTGF-mediated adult beta-cell proliferation after injury. *Mol Metab* 2015;4:584–591.
 71. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
 72. Wang J, Vasaiakar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res* 2017;45:W130–W137.
 73. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. *Nucleic Acids Res* 2005;33:W741–W748.

Received February 2, 2018. Accepted February 8, 2019.

Correspondence

Address correspondence to: Maureen Gannon, PhD, Vanderbilt University Medical Center, 2213 Garland Avenue, MRB IV 7465, Nashville, Tennessee 37232. e-mail: maureen.gannon@vanderbilt.edu; fax: (615) 936-1667.

Acknowledgements

The authors thank members of the Gannon laboratory for helpful discussions throughout the course of this project, and Jennifer Dunn from the Gannon laboratory for technical assistance. They thank Dr Anna Means (Vanderbilt University Medical Center) for assistance with troubleshooting with immunolabeling, Dr Steve Konieczny (Purdue University) for the Mist1 antibody, and Dr Oliver McDonald (Vanderbilt University Medical Center) for his guidance and technical expertise in establishing ChIP in our laboratory. The authors wish to acknowledge the expert technical support of the VANTAGE and VANGARD core facilities, supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA068485) and Vanderbilt Vision Center (P30 EY08126). In particular, they thank Dr Quanhui “Tiger” Sheng for invaluable assistance with the RNA-Seq and ChIP-Seq analysis. Study design: Peter A. Kropp, Xiaodong Zhu, and Maureen Gannon. Data acquisition: Peter A. Kropp and Xiaodong Zhu. Data analysis: Peter A. Kropp, Xiaodong Zhu, and Maureen Gannon. Writing of manuscript: Peter A. Kropp, Xiaodong Zhu, and Maureen Gannon. Funding: Maureen Gannon.

Conflicts of interest

The authors disclose no conflicts.

Funding

Supported in part by the Vanderbilt University Training Program in Stem Cell and Regenerative Developmental Biology (T32 HD05702, P.A.K.), National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases R01 (DK105689, X.Z., M.G.), and by a VA Merit award (1 I01 BX003744-01, M.G.).